VirTrial unveils virtual site monitoring solution for clinical trials

27th May 2020 (Last Updated May 27th, 2020 15:34)

VirTrial has unveiled a new service called Virtual Pre-Site to enable virtual site monitoring visits in the clinical trials industry.

VirTrial unveils virtual site monitoring solution for clinical trials
Virtual Pre-Site enables pharmaceutical sponsors and CROs to evaluate, qualify and routinely monitor research sites for studies. Credit: Science in HD on Unsplash.

VirTrial has unveiled a new service called Virtual Pre-Site to enable virtual site monitoring visits in the clinical trials industry.

Using the virtual site monitoring solution, pharmaceutical sponsors and CROs will be able to assess, qualify and routinely monitor research sites for studies without travelling.

Powered by the VirTrial Virtual Care Management (VCM) platform, Virtual Pre-Site includes the delivery of HD live-streaming glasses.

An on-site Clinical Research Coordinator (CRC) can wear the glasses to provide remote Clinical Research Associate (CRA) access to all aspects of the site virtually simply by walking through the site.

As everything streams to the CRA’s computer screen, the study coordinator can verify the site qualifies for, is trained for, and is performing the study to protocol standards.

The solution streamlines and standardises the study startup and routine monitoring process and ensures consistent information is being collected across all sites.

Furthermore, the HIPAA-compliant platform of Virtual Pre-Site enables the CRA to conduct video interviews with the CRC, as well as the PI to ensure they have the needed patients and time to conduct the study.

Virtual Pre-Site also reduces the time required for study monitoring and slashes associated time and costs.

Virtual Pre-Site vice-president Deric Frost said: “Pharmaceutical sponsors have shown intense interest in this solution due to its ability to cut costs and reduce the time required to evaluate and monitor research sites.

“With the current restriction on travel due to the Covid-19 pandemic, this option enables studies to proceed without delay and facilitates an expedited trial process for sponsors developing drugs to address the current global crisis.”